Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer

This study has been completed.

Study NCT00081289 Information provided by National Cancer Institute (NCI)

First Received: April 7, 2004 Last Updated: July 29, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	May 2011 (Final data collection date for primary outcome measure)

Publications:

Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG. Radiation Therapy Oncology Group 0247: A Randomized Phase II Study of Neoadjuvant Capecitabine and Irinotecan or Capecitabine and Oxaliplatin with Concurrent Radiotherapy for Patients with Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys. 2011 Jul 18; [Epub ahead of print]

Wong SJ, Winter K, Meropol NJ, et al.: RTOG 0247: A randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer. [Abstract] J Clin Oncol 26 (Suppl 15): A-4021, 2008.